These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18491487)

  • 1. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation.
    Cook-Bolden FE; Hamilton SF
    Cutis; 2008 Apr; 81(4):365-71. PubMed ID: 18491487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
    Grimes PE
    Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
    Grimes PE
    Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
    Rendon MI; Barkovic S
    J Drugs Dermatol; 2016 Nov; 15(11):1435-1441. PubMed ID: 28095558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Fabi SG
    Dermatol Surg; 2018 Oct; 44(10):1304-1310. PubMed ID: 29659405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
    Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
    Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma.
    Tirado-Sánchez A; Santamaría-Román A; Ponce-Olivera RM
    Int J Dermatol; 2009 Aug; 48(8):893-5. PubMed ID: 19659872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
    J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.
    Khemis A; Kaiafa A; Queille-Roussel C; Duteil L; Ortonne JP
    Br J Dermatol; 2007 May; 156(5):997-1004. PubMed ID: 17388924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
    Bruce S
    J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
    J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma.
    Guevara IL; Pandya AG
    Int J Dermatol; 2003 Dec; 42(12):966-72. PubMed ID: 14636195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%.
    Grimes P; Watson J
    Cutis; 2013 Jan; 91(1):47-54. PubMed ID: 23461059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
    Grimes PE; Bhawan J; Guevara IL; Colón LE; Johnson LA; Gottschalk RW; Pandya AG
    J Am Acad Dermatol; 2010 Jun; 62(6):962-7. PubMed ID: 20398959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
    Rendon M; Dryer L
    J Drugs Dermatol; 2016 Apr; 15(4):466-75. PubMed ID: 27050702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream.
    Draelos ZD
    Dermatol Surg; 2005 Jul; 31(7 Pt 2):799-804. PubMed ID: 16029670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
    Adalatkhah H; Sadeghi-Bazargani H
    Drug Des Devel Ther; 2015; 9():4219-25. PubMed ID: 26345129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study.
    Rendon M; Cardona LM; Bussear EW; Benitez AL; Colón LE; Johnson LA
    Cutis; 2008 Nov; 82(5):372-8. PubMed ID: 19090343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
    J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.